Biorestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Update

Biorestorative Therapies, Inc. (NASDAQ:BRTX) was the target of a large increase in short interest in May. As of May 29th, there was short interest totaling 6,588,718 shares, an increase of 1,687.2% from the May 14th total of 368,665 shares. Approximately 29.9% of the shares of the stock are short sold. Based on an average trading volume of 65,163,071 shares, the days-to-cover ratio is presently 0.1 days.

Biorestorative Therapies Price Performance

BRTX stock opened at $0.38 on Thursday. The firm has a market capitalization of $9.68 million, a P/E ratio of -0.36 and a beta of 0.67. Biorestorative Therapies has a 52-week low of $0.16 and a 52-week high of $2.05. The company’s 50 day simple moving average is $0.27 and its 200-day simple moving average is $0.61.

Biorestorative Therapies (NASDAQ:BRTX) last released its earnings results on Thursday, May 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.01. The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.31 million. Biorestorative Therapies had a negative return on equity of 508.42% and a negative net margin of 3,088.27%. Sell-side analysts predict that Biorestorative Therapies will post -0.66 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC raised its holdings in shares of Biorestorative Therapies by 102.4% during the 3rd quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock valued at $35,000 after purchasing an additional 12,319 shares in the last quarter. DRW Securities LLC bought a new stake in Biorestorative Therapies in the fourth quarter worth $55,000. Finally, Citadel Advisors LLC acquired a new position in Biorestorative Therapies during the third quarter worth $152,000. Institutional investors and hedge funds own 69.38% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biorestorative Therapies in a research report on Wednesday, May 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

About Biorestorative Therapies

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.